Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

China Isotope & Radiation Corporation Signs Commercial Deal for Pluvicto, China’s First PSMA Radioligand Therapy

Fineline Cube Jan 22, 2026
Company Deals

Matwings Technology Partners with Leading US Biotech on AIACCLBIO Platform for Biopharmaceutical Pipeline

Fineline Cube Jan 22, 2026
Company Deals

AmCellGene Licenses Mesenchymal Stem Cell Therapy for ACLF to Advanced Regeneration in First Chinese Stem Cell Outbound Deal

Fineline Cube Jan 22, 2026
Company Deals

Huadong Medicine Secures Exclusive China Commercialization Rights for Linaprazan Glurate P‑CAB from Sinorda

Fineline Cube Jan 22, 2026
Company Deals

Novavax Licenses Matrix-M Adjuvant to Pfizer in $530M Deal

Fineline Cube Jan 22, 2026
Company Drug Policy / Regulatory

Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate

Fineline Cube Jan 21, 2026
Company Drug

Enhertu Wins China NMPA Approval for Second‑Line HER2‑Positive Gastric Cancer

Fineline Cube Jan 22, 2026
Company Drug

AstraZeneca’s Imfinzi Wins China Approval for Endometrial Cancer, Securing Seventh Indication

Fineline Cube Jan 22, 2026
Company Drug

Pfizer’s Velsipity Approved by European Commission for Moderately to Severely Active Ulcerative Colitis

Fineline Cube Feb 22, 2024

The European Commission (EC) has granted regulatory approval to Pfizer (NYSE: PFE) for its S1P...

Company Drug

FDA Authorizes Biweekly Dosing for J&J’s Tecvayli in Multiple Myeloma Treatment

Fineline Cube Feb 22, 2024

The US Food and Drug Administration (FDA) has granted authorization for a biweekly dosing regimen...

Company

AbbVie CEO Rick González to Retire, Succeeded by Robert A. Michael

Fineline Cube Feb 22, 2024

AbbVie (NYSE: ABBV), a leading US pharmaceutical company, has announced that Rick González, who has...

Company Deals

Sinopharm Plans to Privatize China Traditional Medicine Holdings in a USD 2 Billion Deal

Fineline Cube Feb 22, 2024

China Traditional Medicine Holdings (HKG: 0570; China TCM) has announced that its controlling shareholder, the...

Company Drug

Immune-Onc Therapeutics’ IO-202 Earns Orphan Drug Designation for CMML from US FDA

Fineline Cube Feb 22, 2024

Immune-Onc Therapeutics, the Hangzhou-based subsidiary of US company Immune-Onc Therapeutics Inc., has announced that it...

Company Drug

Innovent Biologics’ Tyvyt Receives Marketing Approval for Multiple Indications in Macau

Fineline Cube Feb 22, 2024

Innovent Biologics Inc., (HKG: 1801), a leading biopharmaceutical company based in China, has announced that...

Company Medical Device

Zylox-Tonbridge Receives UAE Approval for Five Medical Devices, Expands Middle East Presence

Fineline Cube Feb 22, 2024

Zylox-Tonbridge (HKG: 2190), a Chinese specialist in medical devices, has announced a series of product...

Company Drug

MSD’s Belzutifan and Sperogenix’s Vamorolone Targeted for Priority Review by China’s CDE

Fineline Cube Feb 22, 2024

The Center for Drug Evaluation (CDE) website has indicated that Merck, Sharp & Dohme’s (MSD;...

Policy / Regulatory

CDE Opens Consultation on 79th Batch of Generic Drug Reference Preparations

Fineline Cube Feb 22, 2024

The Center for Drug Evaluation (CDE) has issued a call for feedback on the 79th...

Company Drug

Zhongsheng Pharmaceutical Initiates Phase II Trials for Polypeptide Drug RAY1225 in Diabetes and Obesity

Fineline Cube Feb 22, 2024

Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317), a Chinese pharmaceutical company, has announced the initiation...

Company Deals

AstraZeneca Secures Shareholder Approval for $1 Billion Acquisition of Gracell Biotechnologies

Fineline Cube Feb 21, 2024

The proposed acquisition of China-based Gracell Biotechnologies Inc. (Nasdaq: GRCL) by UK pharmaceuticals giant AstraZeneca...

Policy / Regulatory

FDA Issues Warning Letter to Sichuan Deebio for cGMP Violations in API Manufacturing

Fineline Cube Feb 21, 2024

The U.S. Food and Drug Administration (FDA) has issued a warning letter to Sichuan Deebio...

Company Drug

Bayer Advances BAY3018250 into Phase II Trial Following Successful Phase I Completion

Fineline Cube Feb 21, 2024

Germany’s Bayer (ETR: BAYN) has launched a double-blind, placebo-controlled mid-stage trial for its potential first-in-class...

Company Drug

BMS Seeks FDA Priority Review for Krazati in Advanced Colorectal Cancer

Fineline Cube Feb 21, 2024

Bristol Myers Squibb (BMS; NYSE: BMY) has submitted a priority review application to the U.S....

Company Drug

WuXi ATU’s Philadelphia Facility Approved for Amtagvi Production Following FDA Nod

Fineline Cube Feb 21, 2024

WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec (SHA: 603259, HKG:...

Company Deals Drug

HitGen’s Vernalis Partners with Hox Therapeutics to Develop Novel Cancer Inhibitors

Fineline Cube Feb 21, 2024

HitGen Inc. (SHA: 688222), based in China, announced that its wholly owned subsidiary Vernalis (R&D)...

Company Drug

Merck’s Keytruda Under Priority Review for New Indication in Endometrial Carcinoma

Fineline Cube Feb 21, 2024

This week, the U.S. FDA granted priority review status to an indication extension filing from...

Company Deals

Immune-Onc Therapeutics Partners with Roche for Phase Ib/II Study of IO-108 in Liver Cancer

Fineline Cube Feb 21, 2024

Immune-Onc Therapeutics Inc., based in the U.S., is entering into a collaboration with Roche (SWX:...

Company Deals

Innovent Biologics Partners with ImmVirX to Launch Clinical Study Combining Tyvyt and IVX037

Fineline Cube Feb 21, 2024

Innovent Biologics Inc. (HKG: 1801), based in China, has announced the signing of a clinical...

Company

Biogen Appoints Ding Weibo as Head of Asia-Pacific Region, Succeeding Francis Wan

Fineline Cube Feb 21, 2024

Biogen (NASDAQ: BIIB) has announced the appointment of Ding Weibo as the new head of...

Posts pagination

1 … 346 347 348 … 613

Recent updates

  • China Isotope & Radiation Corporation Signs Commercial Deal for Pluvicto, China’s First PSMA Radioligand Therapy
  • Matwings Technology Partners with Leading US Biotech on AIACCLBIO Platform for Biopharmaceutical Pipeline
  • AmCellGene Licenses Mesenchymal Stem Cell Therapy for ACLF to Advanced Regeneration in First Chinese Stem Cell Outbound Deal
  • Huadong Medicine Secures Exclusive China Commercialization Rights for Linaprazan Glurate P‑CAB from Sinorda
  • Enhertu Wins China NMPA Approval for Second‑Line HER2‑Positive Gastric Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

China Isotope & Radiation Corporation Signs Commercial Deal for Pluvicto, China’s First PSMA Radioligand Therapy

Company Deals

Matwings Technology Partners with Leading US Biotech on AIACCLBIO Platform for Biopharmaceutical Pipeline

Company Deals

AmCellGene Licenses Mesenchymal Stem Cell Therapy for ACLF to Advanced Regeneration in First Chinese Stem Cell Outbound Deal

Company Deals

Huadong Medicine Secures Exclusive China Commercialization Rights for Linaprazan Glurate P‑CAB from Sinorda

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.